Navigation Links
MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
Date:8/2/2011

ions, this press release contains forward-looking statements, including with respect to the FDA goal date for MAP Pharmaceuticals' LEVADEX product candidate.  Actual results may differ materially from current expectations based on risks and uncertainties affecting the company's business, including, without limitation, risks and uncertainties relating to the regulatory approval process for the Company's LEVADEX product candidate.  The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.  Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2011, available at http://edgar.sec.gov.

CONTACTS:

Lisa Borland
MAP Pharmaceuticals, Inc.
650-386-3122

Nicole Foderaro
WCG
415-946-1058
nfoderaro@wcgworld.com


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... MARLBOROUGH, Mass. , March 27, 2015 ... ) and privately-held MirImmune LLC, today announced ... license agreement to RXi,s novel and proprietary ... cell-based cancer immunotherapies. The collaboration has the ... and patient friendly cancer treatments that could ...
(Date:3/27/2015)... Concord Medical Services Holdings Limited ("Concord ... a leading specialty hospital management solution provider and ... diagnostic imaging centers in China ... agreement under which Concord Medical Services (International) Pte ... agreed to acquire the Fortis Surgical Hospital from ...
(Date:3/26/2015)... 2015 Huntington Memorial Hospital is the first ... aortic valve replacement (TAVR), a minimally invasive replacement of ... way to replace an aortic valve without a chest ... The procedure is performed by a dedicated ... Alex) Durairaj , MD, interventional cardiologist and Robbin ...
Breaking Medicine Technology:RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2
... (OTC Bulletin Board: SNDZ ), announced today that ... with key brokers and funds.  The purpose of these meetings ... to facilitate funding for Sunridge to execute its business plan ... for this project," states G. Richard Smith, CEO of Sunridge. ...
... NEW YORK, Aug. 24 Regenicin, ... a clinical-stage biotechnology company, announced today that Dr. Joseph Rubinfeld, ... has agreed to join the company,s board of directors. ... efforts of PermaDerm™, Regenicin,s proprietary autologous cultured ...
Cached Medicine Technology:Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors 2
(Date:3/28/2015)... India Network visitor health insurance ... to all visitors who purchase the plan before arrival ... encouraged to purchase the insurance program as soon as ... coverage for pre-existing medical conditions. Parents and grandparents traveling ... conditions with serious consequences to their health. Many visitors ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Pitching speed, player’s ... history of shoulder and elbow injuries, according to new research ... ( AOSSM ) Specialty Day. , “Our findings indicate that ... 20% increase in likelihood of a history of injury, a ... a 12% increase likelihood of a history of injury, and ...
(Date:3/28/2015)... March 28, 2015 Delaying rotator cuff ... necessary, according to research presented today at the American ... Day. , “Our study compared results for 170 patients ... an additional glenohumeral joint capsule release procedure to relieve ... MD, PhD, lead author from St. George Hospital in ...
(Date:3/28/2015)... Francisco, California (PRWEB) March 28, 2015 Andrew ... for original 1960's Who psychedelic concert posters. The Who and ... New York on August 2, 1968. According to Hawley, “The ... playing many concert halls and college campuses. Perhaps the most ... performance with Jim Morrison and the Doors on August 2, ...
(Date:3/28/2015)... March 28, 2015 Healthpointe’s otolaryngologists, medical ... and throat disorders, are now offering a wide ... issue which is characterized by the presence of phantom ... 5 people, tinnitus is a prevalent symptom that can ... it is non-fatal, tinnitus can impede a person’s quality ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... sleep leads to excessive daytime sleepiness, altered mood, and ... accidents. A recent study suggests that obese and overweight ... . ,For the study researchers examined patients' total ... body mass index. More than 1,000 patients completed a ...
... the reason some adolescents experience depression could be abnormal ... between ages 13 to 18, half of who had ... was performed to measure the volume of each teen’s ... hippocampus of patients with depression was, on average, 17 ...
... studies have shown inhaled corticosteroids can reduce the mortality ... results from a study conducted by researchers from the ... than 2,650 patients with COPD who were prescribed inhaled ... period. Nearly 5,400 patients who had never used inhaled ...
... series of laboratory experiments, researchers say they have now ... oil fights cancer.// ,Oleic acid dramatically cut ... of Her-2/neu are associated with aggressive tumors in many ... boosts the effectiveness of the antibody treatment trastuzumab (Herceptin), ...
... world is infected with tuberculosis every second and someone dies ... have discovered easier tests to detect this deadly disease in ... generally done with a gastric lavage. It's an invasive test ... a sputum sample. Sputum is what comes up when you ...
... study shows men who consume three or more alcoholic drinks ... ischemic stroke develops // when an artery in the brain ... than 38,000 participants for 14 years. The male participants responded ... identified 412 cases of ischemic stroke among the study participants. ...
Cached Medicine News:
Used for drainage and retrograde pyelogram in pediatric patients. A stiffening stylet is included to aid in catheter placement. Supplied sterile in peel-open packages. Intended for one-time use....
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... Used for temporary internal ... to the bladder. Supplied sterile ... one-time use. CAUTION: Periodic evaluation ... Sof-Flex stents must not remain ...
... Used for stenting the urethra after ... provide postoperative drainage of the bladder. ... is of sufficient length to allow ... diaper, keeping the inside diaper dry ...
Medicine Products: